Genetic characterization of oncogenic driver mutations (EGFR, KRAS, ALK, ROS) has transformed the management of non-small cell lung cancer (NSCLC) therapy with the introduction of molecularly targeted therapies, allowing an individualized treatment approach [2, 3]. Here, EGFR is linked to non-small cell lung carcinoma.